In addition, CD47 was also overexpressed on hematologic [19, 21–23] and solid [24–26] malignancies, and treatment with agents that block CD47-SIRPα interaction stimulated macrophage phagocytosis in vitro and anti-tumor responses in vivo. This evidence concerns the gene SIRPA and neoplasm.